Skip to content

Clinical Trial to assess the effect of Shilajatu in Renal Stone

A PHARMACO-CLINICAL STUDY FOR EVALUATION OF SHILAJATU FOR PREVENTIVE AND CURATIVE MANAGEMENT OF ASHMARI W.S.R. TO UROLITHIASIS - UroShil

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025239
Enrollment
30
Registered
2020-05-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N202- Calculus of kidney with calculus of ureter

Interventions

Intervention1: Shilajatu (Asphaltum punjabianum): Capsule Shilajatu 500mg twice a day for 1 month. Control Intervention1: Gokshuradi Guggulu: Tab Gokshuradi Guggulu 1gm twice a day for one month.

Sponsors

National Institute of Ayurveda Jaipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient with features urolithiasis and evidence of stone in kidney/ureter/bladder (KUB) less than 15 mm in size

Exclusion criteria

Exclusion criteria: Patients below 18 years and above 60 years, Patient having renal stone size >15mm or stone at lower calyx of kidney, Patients with severe complications such as hydroureteronephrosis, upper urinary tract infections, renal insufficiency, and are requiring immediate or urgent intervention, Patients suffering from serious systemic disorders such as Diabetes mellitus, Hypertension etc. or any history of hypersensitivity to any herbal formulation, Pregnant or lactating women

Design outcomes

Primary

MeasureTime frame
Stone Free RateTimepoint: 0, 4 week, 12 week

Secondary

MeasureTime frame
Clinical Improvement in SymptomsTimepoint: 0, 4 week, 12 week

Countries

India

Contacts

Public ContactDr Rajendra Kumar

National Institute of Ayurveda, Jaipur

rajanpaliwal25@gmail.com9784361336

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026